Pfizer (PFE) is planning to sweeten its offer again for Metsera (MTSR), the weight-loss drug startup at the center of a bidding war that also involves Novo Nordisk (NVO), The Wall Street Journal’s Lauren Thomas and Jonathan Rockoff report. Pfizer is making plans to deliver a fresh bid Wednesday, according to people familiar with the matter, ahead of a deadline it has to respond to Novo Nordisk’s latest proposal. Under the terms of its existing merger agreement with Metsera, Pfizer’s next likely step is to match Novo Nordisk’s offer, one of the people said.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Pfizer says ‘we remain confident in the merits of our claims’ against Metsera
- Novo Nordisk tells STAT Metsera deal structure ‘consistent with antitrust laws’
- Metsera says will accept superior bids until closing, Bloomberg reports
- Metsera falls after FTC raises filing concerns over Novo bid
- 3 Best Dividend Aristocrat Stocks to Buy Now, 11/05/2025